Tablet inactive ingredients

The preferred and easiest intake of medicines is by oral ingestion in the form of tablets. Tablets today contain a combination of an active pharmaceutical ingredient and a (polymer) excipient-the inactive ingredient that delivers the pharmaceutical active... 

The FDA s regulations define drug product as a finished dosage form, for example, a tablet, capsule, solution, etc., that contains an active drug ingredient generally, but not necessarily, in association with inactive ingredients. 21 C.F.R. 210.3(4). 

Mintezol (Thiabendazole) is an anthelmintic provided as a suspension, containing 500 mg thiabendazole per 5 mL. The suspension also contains sorbic acid 0.1% added as a preservative. Inactive ingredients in the tablets are acacia, calcium phosphate, flavors, lactose, magnesium stear-... 

All active and inactive ingredients are in exactly the same proportion between different strengths (e.g., a tablet of 50-mg strength has all the inactive ingredients, exactly half that of a tablet of 100-mg strength, and twice that of a tablet of 25-mg strength). 

For modified-release tablets, when the drug product is in the same dosage form but in a different strength, is proportionally similar in its active and inactive ingredients, and has the same drug release mechanism, an in vivo BE determination of one or more lower strengths can be waived based on dissolution profile comparisons, with an in vivo... 

Formulation design is based on the physical, chemical, and biopharmaceutical properties of a drug substance. A formulation for direct compression is composed of active pharmaceutical ingredients and other inactive ingredients such as fillers, binders, dis-integrants, flow aids, and lubricants. Simplicity is the basis of good formulation design. Minimally, a direct compression tablet formulation must meet requirements for manufacturability, uniformity of dose, physical and chemical stability, appropriate dmg release profiles, and bioavailability. In addition, the formulation must meet many quality standards and special requirements to ensure the efficacy and safety of the product. 

Besides the active ingredients, antacid tablets also contain inactive ingredients, such as starch, which act as a binder or filler. The efficacy of an antacid tablet is its ability to neutralize HC1. The more HC1 that is neutralized, the more effective the antacid pill. (You must have heard the competing advertisement claims of different commercial antacids Turns neutralizes one-third more stomach acid than Rolaids. )... 

Add exactly 50 mL 0.2 N HC1 to each Erlenmeyer flask from the buret. Also, add a few drops of thymol blue indicator. Gently stir with the stirring rods to disperse the tablets. (Some of the inactive ingredients may not go into solution and will settle as a fine powder on the bottom of the flask.) At this point the solution should be red (the color of thymol blue at acidic pH). If either of your solutions does not have red coloration, add 10 mL 0.2 N HC1 from the refilled buret and make certain that the red color will persist for more than 30 sec. Record the total volume of 0.2 N HC1 added to each flask on your Report Sheet (3). 

State the composition the name and amount of each active and inactive ingredient in the drug product in the form in which it is to be distributed (e.g., amount per tablet). Describe the dosage form full details as to type and physical characteristics (e.g. shape, color, coating, and hardness). 

Provides the chemical name of the drug and a structural diagram. States whether the drug is in tablet form, capsules, liquid, etc., and how it should be given (topically, orally, by injection, or by parenteral administration). Lists inactive ingredients. 

GRAS listed. Accepted for use in Europe as a food additive. Included in the FDA Inactive Ingredients Guide (oral preparations and buccal or sublingual tablets). Included in the Canadian List of Acceptable Non-medicinal Ingredients. Included in nonparenteral medicines licensed in the UK. 

Included in the FDA Inactive Ingredients Guide (oral tablets and topical sponge). Included in nonparenteral medicines licensed in the UK. 

---